Correlation Between Caribou Biosciences and Corvus Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Caribou Biosciences and Corvus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Caribou Biosciences and Corvus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Caribou Biosciences and Corvus Pharmaceuticals, you can compare the effects of market volatilities on Caribou Biosciences and Corvus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Caribou Biosciences with a short position of Corvus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Caribou Biosciences and Corvus Pharmaceuticals.

Diversification Opportunities for Caribou Biosciences and Corvus Pharmaceuticals

0.6
  Correlation Coefficient

Poor diversification

The 3 months correlation between Caribou and Corvus is 0.6. Overlapping area represents the amount of risk that can be diversified away by holding Caribou Biosciences and Corvus Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Corvus Pharmaceuticals and Caribou Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Caribou Biosciences are associated (or correlated) with Corvus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Corvus Pharmaceuticals has no effect on the direction of Caribou Biosciences i.e., Caribou Biosciences and Corvus Pharmaceuticals go up and down completely randomly.

Pair Corralation between Caribou Biosciences and Corvus Pharmaceuticals

Given the investment horizon of 90 days Caribou Biosciences is expected to under-perform the Corvus Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Caribou Biosciences is 1.1 times less risky than Corvus Pharmaceuticals. The stock trades about -0.05 of its potential returns per unit of risk. The Corvus Pharmaceuticals is currently generating about 0.15 of returns per unit of risk over similar time horizon. If you would invest  158.00  in Corvus Pharmaceuticals on September 24, 2024 and sell it today you would earn a total of  341.00  from holding Corvus Pharmaceuticals or generate 215.82% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Caribou Biosciences  vs.  Corvus Pharmaceuticals

 Performance 
       Timeline  
Caribou Biosciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Caribou Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental drivers, Caribou Biosciences is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.
Corvus Pharmaceuticals 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Corvus Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Corvus Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Caribou Biosciences and Corvus Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Caribou Biosciences and Corvus Pharmaceuticals

The main advantage of trading using opposite Caribou Biosciences and Corvus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Caribou Biosciences position performs unexpectedly, Corvus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corvus Pharmaceuticals will offset losses from the drop in Corvus Pharmaceuticals' long position.
The idea behind Caribou Biosciences and Corvus Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Other Complementary Tools

Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals